Search Within

Rohit Bose

Formats
  1. Meeting Abstract (4)
  2. Journal Article (2)
Groups
  1. Department of Medicine (4)
  2. Hematologic Malignancies, Division of (4)
  3. Solid Tumor Oncology Division (4)
  4. Center for Hematologic Malignancies (3)
  5. Epidemiology and Biostatistics (3)
  6. Executive Committee, Center for Hematologic Malignancies (3)

More Groups

People
  1. Charles Sawyers (3)
  2. Wassim Abida (3)
  3. Howard Scher (2)
  4. John Wongvipat (2)
  5. Joshua Armenia (2)
  6. Michael Doran (2)

More People

Years
  1. 2022 (1)
  2. 2021 (1)
  3. 2020 (1)
  4. 2018 (1)
  5. 2017 (1)
  6. 2016 (1)
Publications
  1. Journal of Clinical Oncology (4)
  2. JCO Precision Oncology (1)
  3. Nature (1)
Publishers
  1. American Society of Clinical Oncology (5)
  2. Nature Publishing Group (1)

Results (6)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prospective clinical genomic profiling of Ewing sarcoma: ERF and FGFR1 mutations as recurrent secondary alterations of potential biologic and therapeutic relevance
    Journal Article

    Ogura, K.; Elkrief, A.; Bowman, A. S.; Koche, R. P.; de Stanchina, E.; Benayed, R.; Mauguen, A.; Mattar, M. S.; Khodos, I.; Meyers, P. A.; more...
    JCO Precision Oncology (2022)

    Fulltext@MSK | Save
  • Implementation of clinician-facing prostate cancer therapeutic clinical trial decision tool at a comprehensive cancer center
    Meeting Abstract

    Borno, H.; Li, P.; Zhang, S.; Idossa, D.; Desai, A.; Rodvelt, T. J.; Bose, R.; Koshkin, V. S.; Chou, J.; Friedlander, T. W.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Treatment outcomes in metastatic prostate cancer patients with DNA damage repair mutations
    Meeting Abstract

    Kwon, D.; Wright, F.; Zhang, L.; Chou, J.; Borno, H.; Desai, A.; Oh, D. Y.; Pollock, Y. G.; Bose, R.; Huang, F. W.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • c15-153: Randomized phase IB/II study of enzalutamide with and without ribociclib in patients with metastatic castrate resistant, chemotherapy naive prostate cancer that retains RB expression
    Meeting Abstract

    Kelly, W. K.; Godwin, J. L.; Hoffman-Censits, J. H.; Knudsen, K. E.; De Leeuw, R.; Leiby, B. E.; Southwell, T.; Hubert, C.; Smith, D. C.; Chatta, G. S.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis
    Journal Article

    Bose, R.; Karthaus, W. R.; Armenia, J.; Abida, W.; Iaquinta, P. J.; Zhang, Z.; Wongvipat, J.; Wasmuth, E. V.; Shah, N.; Sullivan, P. S.; more...
    Nature (2017)

    Fulltext@MSK | Save
  • Investigation of a frequently mutated transcriptional repressor in prostate cancer, in particular its role in modulating androgen signaling and its effects on TMPRSS2-ERG dependent tumor maintenance
    Meeting Abstract

    Bose, R.; Abida, W.; Iaquinta, P.; Karthaus, W.; Armenia, J.; Wongvipat, J.; Doran, M.; Hieronymus, H.; Philip, W.; Liang, Y. P.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save